Key Highlights

  • Revenue rose 10.7% to A$3.32 billion, and underlying NPAT climbed 25.8% to A$381.2 million.
  • Commodities Revenue grew 18.8% organically, mainly from higher mineral exploration activity.
  • Financial Leverage fell to 1.5 times, below the group's target range.
  • The final Dividend was 23.1 cents per share, partially franked, bringing the full-year total to 42.5 cents.

Why did ALS Limited (ASX:ALQ) report a record result for the year to March 2026, and how durable are the drivers? On 18 May 2026 the testing and laboratory group reported revenue of A$3.32 billion and underlying net profit after tax of A$381.2 million, both higher than the prior year, with its Commodities division growing encouragingly on higher mineral exploration activity. The answer is that ALS combined a cyclical tailwind in Mining with steadier growth in food testing and tighter cost control.

The FY26 result

ALS has a financial year ending 31 March.

Revenue: A$3.32 billion, up 10.7 per cent.

Underlying EBIT: A$599.0 million, up 19.3 per cent, with the Margin up 129 basis points to 18.0 per cent.

Underlying net profit after tax: A$381.2 million, up 25.8 per cent.

Statutory net profit after tax: A$318.7 million, up 24.4 per cent.

Free cash flow: A$674.1 million, with EBITDA cash conversion of 92 per cent.

Final dividend: 23.1 cents per share, partially franked; full-year dividend 42.5 cents per share.

What drives the business

Commodities: Revenue grew 18.8 per cent organically, mainly from higher mineral exploration activity. This division tests geochemical samples from exploration drilling, so volumes follow explorer funding and drilling activity.

Life Sciences: Revenue rose 6 per cent, led by the Food business. Food, pharmaceutical and consumer testing tends to be steadier because it is linked to regulation and quality standards.

Environmental: Softer in the Americas because of internal and market challenges that management said are being addressed. Industrial Materials is a further reporting area, for which management expects high single-digit growth in FY27.

The mix matters. The Commodities division is the most encouraging contributor to growth in FY26, but it is also the most cyclical. If exploration funding tightened, volumes and margins could fall quickly, while the more stable Life Sciences Business would cushion the impact.

Balance sheet and investment

Financial leverage fell to 1.5 times, below the group's target range, helped by cash generation and a successful Equity raising. The company built four new hub laboratories across Minerals and Environmental, and said new Sydney and Lima laboratories are to be commissioned in the second half of FY27.

The "Lab of the Future" initiative, which uses automation, digital infrastructure and artificial intelligence, is central to the margin story. Automation can lift throughput and lower unit costs, but the savings depend on volumes being high enough to justify the investment.

FY27 outlook

Management guided qualitatively to mid to high single-digit organic revenue growth with further margin expansion. By division, it expects double-digit growth in Minerals, high single-digit growth in Industrial Materials and improved mid-single-digit organic growth in Life Sciences. These are management expectations, not outcomes, and they assume continuing strength in mining activity.

Competitive position

Its advantages are a global footprint, long relationships with miners and a reputation for quality in geochemistry. A particular point of interest is the Investment in hub laboratories, which can improve efficiency but add fixed costs. In Commodities, ALS benefits when clients need rapid turnaround and large capacity, which scale supports.

Key risks

Exploration cycle: Commodities growth reflects higher exploration spending, which can reverse.

Environmental division: Softness in the Americas could continue if the internal and market challenges persist.

Macroeconomic and Supply chain conditions: Management flagged global macro conditions and supply chain risks.

Execution and Capital intensity: New laboratories and automation projects require investment and careful commissioning.

Foreign exchange: With operations across many countries, currency movements affect reported earnings.

What to watch next

Useful indicators include Commodities volumes against the double-digit growth guided for Minerals, evidence of Environmental stabilising, the commissioning of the Sydney and Lima laboratories, and any disclosure of Acquisition activity.

Bottom line

ALS delivered an encouraging FY26 on a combination of exploration-driven growth, margin gains and encouraging cash generation, and it has strengthened its balance sheet. The main question is how much of the improvement reflects a cycle that could turn and how much reflects structural gains from its laboratory investments. The result is a snapshot of an encouraging year rather than a forecast.